Natural glycosides — including cardiac glycosides such as digoxin precursors, as well as synthetically reproduced equivalents — and their salts, ethers, esters, and other chemical derivatives are traded under this heading primarily as pharmaceutical intermediates and botanical-derived APIs. The distinction between naturally extracted and synthetically reproduced glycosides is commercially significant: sourcing, quality specifications, and regulatory documentation differ substantially between plant-extracted and fermentation- or synthesis-derived material. FDA entry review applies to imported pharmaceutical-grade glycoside materials, and importers should be prepared to provide certificates of analysis and facility registration data.

AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.